Significance and implications of FDA approval of pembrolizumab for biomarker-defined diseaseMichael M. Boyiadzis, John M. Kirkwood, John L. Marshall, Colin C. Pritchard, Nilofer S. Azad, James L. Gulley14 May 2018
Immunotherapy for Merkel cell carcinoma: a turning point in patient careIsaac S. Chan, Shailender Bhatia, Howard L. Kaufman, Evan J. Lipson23 March 2018
Current clinical trials testing the combination of immunotherapy with radiotherapyJosephine Kang, Sandra Demaria, Silvia Formenti20 September 2016
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapyHasan Rehman, Ann W. Silk, Michael P. Kane, Howard L. Kaufman20 September 2016
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Claud Grigg, Naiyer A. Rizvi16 August 2016
Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccineDavid B. Page, Tyler W. Hulett, Traci L. Hilton, Hong-Ming Hu, Walter J. Urba, Bernard A. Fox17 May 2016